Helsinn announces publication of anamorelin ROMANA 1 and
ROMANA 2 Phase III studies in The Lancet Oncology
- Pivotal data from anamorelin ROMANA 1 and ROMANA 2 Phase III studies published in
world-leading, peer-reviewed medical journal - Study showed anamorelin significantly improved lean body mass, body weight and
symptom burden including appetite in NSCLC patients with cachexia
Linkedin